Azithromycin is a new
acid-stable 15-membered-ring
macrolide that exhibits an extended half-life and excellent tissue distribution, including distribution in the lung. We compared its in vivo activity with that of
erythromycin using two models of Streptococcus pneumoniae
pneumonia, namely, a model of acute
infection in Swiss mice and a model of subacute
infection in C57BL/6j mice. Female mice were infected by oral delivery into the trachea of 10(5) CFU of a virulent serotype 3 strain of S. pneumoniae (P 4241). Prophylactic and therapeutic treatments were given orally (p.o.) or subcutaneously (s.c.) by various regimens. In the model of subacute
infection, a single dose of
azithromycin, 25 mg/kg, given p.o. 7 h before
infection protected 92% of the mice, while
erythromycin was completely ineffective. In the model of acute
infection, a single dose of
azithromycin, 50 mg/kg, given s.c. 24 h prior to challenge protected 80% of the mice, whereas only 35% of the mice survived with
erythromycin, 50 mg/kg, 1 h before challenge.
Therapy, which was studied exclusively in the model of subacute
infection, was initiated 48 h postinfection. Two doses of 12.5 mg/kg given p.o. 12 h apart resulted in 80% survival of mice treated with
azithromycin versus 7% survival of mice treated with
erythromycin. Pulmonary clearance of bacteria was consistent with the survival rates. Two doses (25 mg/kg) of
azithromycin given s.c. at 48 and 65 h after
infection led to complete clearance of bacteria from the lungs and blood, whereas
erythromycin-treated mice remained bacteremic. The pharmacokinetics of
azithromycin account for its superior efficacy against S. pneumoniae
pneumonia relative to the efficacy of
erythromycin.